ZNTL — Zentalis Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1725160 ·
Last close
$1.49
Market Cap
$146.42M
52W High
$6.95
52W Low
$1.28
ADV30
1,335,001
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -31,154,000 | -28,815,000 | 270,193,000 | 24,029,000 | 65,306,000 |
| Jun 2026 | 0 | — | -44,391,000 | -42,286,000 | 215,330,000 | 24,783,000 | 71,684,000 |
| Mar 2026 | 0 | — | -37,855,000 | -35,352,000 | 253,066,000 | 31,930,000 | 70,386,000 |
| Dec 2025 | 0 | — | -37,393,000 | -35,216,000 | 288,967,000 | 35,995,000 | 72,763,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-133,839,000
Investing CF
$37,181,000
Financing CF
$81,615,000
CapEx
$-34,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.80
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,297,908,000
Inventory
—
Receivables
$0
ST Investments
$204,864,000
EBIT TTM
$-150,793,000
Pretax Income TTM
$-140,851,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -145,012,000 | -137,060,000 | 288,967,000 | 72,763,000 | 216,204,000 | -125,247,000 |
| Dec 2024 | 67,425,000 | -187,458,000 | -165,839,000 | 430,337,000 | 93,151,000 | 337,186,000 | -170,860,000 |
| Dec 2023 | 0 | -253,941,000 | -292,191,000 | 551,688,000 | 114,297,000 | 437,284,000 | -207,822,000 |
| Dec 2022 | 0 | -227,287,000 | -236,806,000 | 539,310,000 | 105,286,000 | 433,803,000 | -163,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-139,545,000
OpCashFlow TTM
—
Assets (Latest)
$215,330,000
Forward EPS
$-1.52
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.36 · call volume: 79 · put volume: 183Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRXA | Veraxa Biotech AG - Post de-SPAC | $147.06M | $1.04 | — |
| RNA | Atrium Therapeutics, Inc. | $139.78M | $6.48 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $138.97M | $1.00 | — |
| SION | Sionna Therapeutics, Inc. | $138.87M | $3.07 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $155.69M | $1.94 | — |
News headlines (Yahoo Finance, 1h cache)
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-09 21:05 · Yahoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-03 21:15 · Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 22:00 · Yahoo
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
2026-10-23 14:15 · Yahoo
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
2026-10-18 22:05 · Yahoo
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
2026-10-05 11:55 · Yahoo
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-08-17 20:01 · Yahoo
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
2026-08-13 20:01 · Yahoo
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
2026-07-20 13:26 · Yahoo
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
2026-07-17 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.